Table 2.
Cannabinoids (generally) | Inhibition of cytokine storms, improvement of lung function, reduction of inflammation, bronchi dilatation, alleviation of symptoms (suffocation, cough). | [3,24,29,30,42] |
CBD | Decrease of secretion of inflammatory cytokines, such as IL-6, IL-8, CCL2, and CCL7. | [27] |
CBD | Improvement of blood oxygen saturation and the function of lung tissue; decrease in IL-6 levels, as well as neutrophil and lymphocyte infiltration. | [33] |
THC | Apoptosis of mononuclear cells infiltrating lungs, downregulation of alveolar macrophages, neutrophils, lymphocytes CD4+, CD8+, NK, NKT cells and proinflammatory cytokines (IFN-γ, IL-1β, IL-2, or TNF-α). | [38,39,40,41] |
CB2 receptors | Downregulation of immune cell infiltration in the lungs, as well as levels of IFN-γ, MIP-1α; increased production of IL-10. | [35] |
CB1 receptors | Reduction of immune cell influx, cytokine production, and alleviation of lung pathology. | [36] |
CBD, cannabidiol; CCL, CC chemokine ligand; THC, Δ9-tetrahydrocannabinol; NK, natural killer; NKT, natural killer T; CB, cannabinoid; IFN-γ, interferon γ; MIP−1α, macrophage inflammatory protein 1α.